FERDEGHINI, Marco
 Distribuzione geografica
Continente #
NA - Nord America 6.786
EU - Europa 4.074
AS - Asia 1.843
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 9
AF - Africa 5
Totale 12.738
Nazione #
US - Stati Uniti d'America 6.765
GB - Regno Unito 1.314
CN - Cina 1.027
SG - Singapore 704
FI - Finlandia 450
FR - Francia 442
RU - Federazione Russa 402
DE - Germania 393
IE - Irlanda 341
SE - Svezia 303
IT - Italia 178
UA - Ucraina 165
VN - Vietnam 37
TR - Turchia 27
BE - Belgio 22
CA - Canada 18
HK - Hong Kong 14
ES - Italia 11
AU - Australia 10
AT - Austria 7
JP - Giappone 7
NL - Olanda 7
EU - Europa 6
IN - India 6
PL - Polonia 6
BR - Brasile 5
DK - Danimarca 4
KR - Corea 4
RO - Romania 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BG - Bulgaria 3
EG - Egitto 3
ID - Indonesia 3
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
LI - Liechtenstein 2
LT - Lituania 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
RS - Serbia 2
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CH - Svizzera 1
CL - Cile 1
CM - Camerun 1
EE - Estonia 1
GE - Georgia 1
IQ - Iraq 1
IR - Iran 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
ME - Montenegro 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 12.738
Città #
Jacksonville 1.637
Southend 1.106
Chandler 1.036
Woodbridge 844
Singapore 619
Ann Arbor 589
Houston 409
Dublin 340
Ashburn 241
Wilmington 188
Lawrence 184
Princeton 184
Nanjing 140
Sindelfingen 131
Boardman 111
New York 98
Helsinki 91
Jinan 88
Shenyang 88
Hebei 85
Beijing 79
Philadelphia 58
Tianjin 55
Changsha 49
Verona 47
Detroit 45
Nanchang 44
Haikou 37
Jiaxing 37
Dong Ket 36
Milan 35
Norwalk 35
Hangzhou 34
Ningbo 34
Zhengzhou 29
Falls Church 24
Los Angeles 23
Brussels 22
Guangzhou 22
Taizhou 21
Bologna 20
Santa Clara 20
Washington 19
Auburn Hills 17
Lanzhou 17
Taiyuan 16
Chicago 15
Dearborn 15
Lancaster 15
Tappahannock 15
Düsseldorf 13
Toronto 13
Seattle 11
Hong Kong 10
Redwood City 10
San Francisco 9
Fuzhou 8
Dallas 7
Kent 7
San Diego 7
Tokyo 7
Vigo 7
Melbourne 6
Ypsilanti 6
Andover 5
Edinburgh 5
Fairfield 5
Hanover 5
Moscow 5
Redmond 5
Rome 5
Mehlingen 4
Montefiore Conca 4
Obninsk 4
Seoul 4
Cairo 3
Canberra 3
Chennai 3
Dongguan 3
Florence 3
Frankfurt am Main 3
Greifswald 3
London 3
Marseille 3
Messina 3
North Bergen 3
Padova 3
Paris 3
Phoenix 3
Secaucus 3
Shanghai 3
Sofia 3
Sossano 3
Stockholm 3
Warsaw 3
Amsterdam 2
Auckland 2
Belgrade 2
Budapest 2
Central 2
Totale 9.386
Nome #
[111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas 149
Gated reconstruction in 18FDG PET-CT quantitative imaging: impact on SUV estimation in lung tumors 135
SU-E-J-168: 4D-PET for Target Volume Delineation in Respiratory-Gated Radiation Therapy. 123
A mathematical model of thyroid mass reduction after radioiodine therapy of Graves’ disease 121
Humanization of care in pediatrics and built-in psychological support in nuclear medicine [Umanizzazione delle cure in età pediatrica e assistenza psicologica integrata in Medicina nucleare] 119
Espressione di Claudina-1 e 7 nel carcinoma papillare della tiroide con comportamento clinico aggressivo 118
First human Cerenkography. 113
Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa. 110
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. 106
Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. 99
Valutazione comparativa dell'acquisizione volumetrica tiroidea con ecografia convenzionale B-Mode (US) ed ecografia volumetrica (VUS) 98
rhTSH-Stimulated Postsurgical Thyroid Remnant Ablation in Differentiated Thyroid Cancer: 1.85 vs 3.7 GBq I-131 Activity 96
Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements 95
Lazaroid U-74389F attenuates phorbol ester-induced lung injury in rabbits 94
Role of dual-point FDG PET/CT in prone position and fused PET/MR; correlation with biologic prognostic parameters in breast cancer 92
Acute suppression of parathyroid activity during hemofiltration 91
A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma 87
Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. 86
Relation of fetal growth to maternal responses to oral glucose tolerance test throughout gestation 86
Tumor-associated trypsin inhibitor (TATI) and renal function 84
Effect of anabolic treatment on the serum levels of gonadotropins, testosterone, prolactin, thyroid hormones and myoglobin of male athletes under physical training 84
Autonomous thyroid nodule and percutaneous ethanol injection [letter] [see comments] 83
The relationship between maternal relaxation and plasma beta-endorphin levels during parturition 83
A new luminescence immunoassay for thyrotropin using coated tubes: evaluation and comparison with immunoradiometric assay 83
Correlation between intracoronary physiology and myocardial perfusion imaging in patients with severe aortic stenosis 83
Clinical validation of the new ELSA-CA 125 II assay: report of a European multicentre evaluation 82
Serum interleukin-6 levels in uterine malignancies. Preliminary data 82
Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal. 82
Optimized PET Imaging for 4D Treatment Planning in Radiotherapy: the Virtual 4D PET Strategy 82
A Dirichlet process mixture model for automatic (18)F-FDG PET image segmentation: Validation study on phantoms and on lung and esophageal lesions 82
Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix 81
CAM26, CAM29 and mucin-like carcinoma associated antigen in epithelial ovarian cancer 81
Comparison of plasma and urinary methods for the direct measurement of the thyroxine to 3,5,3' - triiodothyronine conversion rate in man 81
T-helper 1 and 2 activation with fresh or cultured allo- or xenoislets 80
Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer 79
Effects of the ablation of the submaxillary gland on the rat testis 79
Hypothalamo-pituitary function in four cases of true precocious puberty 79
Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between rhTSH stimulation and prolonged levothyroxine withdrawal. 79
Off-Label Use of Sunitinib in Patients with Advanced, Epithelial Thyroid Cancer: A Retrospective Analysis. 79
CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer 78
Analytical and clinical assessment of a commercial kit for the simultaneous determination of free thyroxine and thyrotropin 78
Serum tumour-associated trypsin inhibitor (TATI) and renal function 78
Functional Imaging and Peptide Receptor Radionuclide Therapy 78
A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma 77
A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology 77
Relationship between the circulating levels of adenohypophyseal hormones in blood and in cerebrospinal fluid 77
Assessment of tumor-associated trypsin inhibitor (TATI) as a marker of renal function. 77
Age and Gender Substantially Influence the Relationship Between Thyroid Status and the Lipoprotein Profile: Results from a Large Cross-Sectional Study. 77
A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult Hypoglycemia 77
Blood markers of early and late airway responses to allergen in asthmatic subjects. Relationship with functional findings 76
Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer 76
[Serum levels of CA 125, CA 19-9, TPA, CEA and CA 50: useful evaluation parameters in the diagnosis of ovarian cancer] 76
Can insulin action induce myocardial texture alterations in essential hypertension? 76
Plasma leptin levels in newborns from normal and diabetic mothers. 76
Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). 76
A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours 76
Radioimmunoassay of unconjugated and total serum estetrol using a 125I-iodinated tracer 75
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 75
Soluble interleukin-2 receptor release during culture of human lymphocytes with human, porcine, or bovine islets and the effect of culture and cryopreservation 74
Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders 74
Somatotropic axis and body weight in pre-menopausal and post-menopausal women: evidence for a neuroendocrine derangement, in absence of changes of insulin-like growth factor binding protein concentrations 74
[Bromocriptine therapy from the 2d month of pregnancy induces regression of neuro-ophthalmologic complications caused by macroprolactimona] 74
Combined evaluation of some tumor associated antigens in the monitoring of integrated surgical and chemotherapeutic treatment of epithelial ovarian cancer 73
Circulating levels of IGF-I in patients with chronic uremia on conservative dietary treatment. 73
Comparison between serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS 19-9 reactivity in malignant and benign ovarian tumors 72
Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses 72
[Growth factors and oncogenes in development and carcinogenesis. Role of the epidermal growth factor system] 72
Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia 72
[Primary empty sella syndrome. Clinical and radiological study, and evaluation of pituitary function] 72
Anomalous between-laboratory variability in a collaborative study of carcinoembryonic antigen immunoassay [letter] 72
Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. 72
High-performance liquid chromatographic separation of iodoamino acids for tracer turnover studies of thyroid hormones in vivo 71
Preoperative serum intercellular adhesion molecule-1 (ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) in patients with epithelial ovarian cancer 70
Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer 70
Anticlastogenic Effect of Ginkgo biloba Extract in Graves' Disease Patients Receiving Radioiodine Therapy 70
Preoperative serum E-cadherin assay in patients with ovarian carcinoma 69
[Tumor markers: new prospects in the diagnosis and clinical monitoring of malignant epithelial neoplasms of the ovary] 69
Hyperprolactinemic amenorrhea induced by an intrasellar epithelial cyst 69
Total and free (dialyzable) cortisol assay in plasma: comparison of two RIA methods involving the use of antibody-coated test tubes 69
Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma 68
The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients 68
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma 68
The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma 68
The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data 68
Radioimmunoassay of free cortisol with antiserum-coated tubes and 125I-labeled cortisol [letter] 68
Comet assay on children's leukocytes 8 years after the Chernobyl disaster 67
Preoperative evaluation of CA 125 and CA 19-9 serum levels in patients with ovarian masses 67
Role of serum carrier proteins in the peripheral metabolism and tissue distribution of thyroid hormones in familial dysalbuminemic hyperthyroxinemia and congenital elevation of thyroxine-binding globulin 67
External quality control survey for alpha-fetoprotein assay 67
Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer 66
Platelet activation in outpatients undergoing esophagogastroduodenoscopy 66
Human placental lactogen (hPL) deficiency in a normal pregnancy 66
Human seminal transferrin: correlation with seminal and hormonal parameters 66
Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB-154) administration 66
Multiple radioimmunological determinations of free (diffusible) steroid hormones (cortisol, progesterone, 17alpha OH-progesterone and estradiol) in the same plasma dialyzate after equilibrium dialysis 66
Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects. 66
RET mutation and increased angiogenesis in medullary thyroid carcinomas 66
Determination of serum levels of different cytokeratins in patients with uterine malignancies 65
Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women 65
Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer 65
Totale 8.004
Categoria #
all - tutte 44.300
article - articoli 42.123
book - libri 0
conference - conferenze 1.455
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 722
Totale 88.600


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020961 0 0 0 0 0 204 94 175 35 187 20 246
2020/20211.795 107 380 78 175 221 206 10 171 162 5 201 79
2021/2022955 38 121 7 37 35 24 13 81 81 49 127 342
2022/20232.784 228 176 256 505 351 599 15 238 274 17 85 40
2023/20241.097 79 143 109 257 86 136 24 35 7 13 115 93
2024/20251.133 250 192 31 497 158 5 0 0 0 0 0 0
Totale 12.780